Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
IRADIMED CORP
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-77.3% vs price
Base Case (Median)
-68.7% vs price
Bull Case (75th pct.)
-51.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $18.97 | -78.1% | High (40%) |
| PE Comparable | $40.75 | -52.9% | Medium (25%) |
| Growth Trajectory DCF | $60.92 | -29.6% | Medium (20%) |
| Graham Number | $17.27 | -80.1% | Medium (40%) |
| EV/EBITDA | $27.10 | -68.7% | Medium (20%) |
| EV/FCF | $43.30 | -50.0% | Medium (20%) |
| Earnings Power Value | $20.28 | -76.6% | Medium (50%) |
Based on 7 out of 7 methods, IRMD appears overvalued at the current price of $86.57. The base case fair value of $27.10 implies 68.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.